We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific's Restructuring Plan & Innovation Offer Hope
Read MoreHide Full Article
On Jul 13, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) . The stock currently carries a Zacks Rank #2 (Buy).
We are currently looking forward to the company’s recently introduced global restructuring plan, the execution of which will result in the fulfillment of its margin leverage goals and help produce low-to-mid-teens EPS growth, ahead of the industry average.
Without revealing much detail, the company noted that the program will focus on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of its Plant Network Optimization (PNO) strategy, and expanding operational efficiencies to support its operating income margin goals.
Management has chalked out several key activities under the program, which include strengthening global infrastructure through evolving global real estate and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions, and continued implementation of the company's ongoing PNO strategy. This strategy is intended to simplify Boston Scientific's manufacturing plant structure by transferring certain production lines among facilities. These activities are expected to be initiated in the second quarter of 2016 and substantially completed by year-end 2018.
We are also encouraged about National Institute for Health and Care Excellence’s (NICE) positive guidance on Boston Scientific’s GreenLight XPS Laser Therapy System, for the treatment of prostatic enlargement, known as benign prostatic hyperplasia.
We have noted that the company continues to strengthen its core businesses and invest in new technologies and global markets, which accounted for the sales upside across most of its businesses and regions in the reported quarter. According to Boston Scientific, its PNO strategy has simplified its manufacturing plant structure by shifting certain production lines among facilities. The full benefit of PNO, which has been completed recently, should start to reflect in the company’s Rhythm Management adjusted operating margin through the second half of 2016.
An important aspect of the company’s growth strategy is to continue pursuing development opportunities outside the U.S. by expanding global presence, inclusive of the emerging markets. In the first quarter of 2016, business from the emerging markets registered a robust 21% organic growth rate, well ahead of the company’s target of reaching 15% of sales by 2017 from 8% in 2013.
Boston Scientific hopes to sustain its strong overall international performance taking into concern several key new product launches that are in the early stages of their rollout. The company is also optimistic about its core cardiology segment which is gradually stabilizing, with growth witnessed in the BRIC nations.
Meanwhile, sluggish Cardiac Rhythm Management (CRM) sales over the recent past continue to weigh on the stock. Although Boston Scientific currently expects a rebound in its CRM performance in the second quarter and second-half of 2016, we remain on the sidelines based on the persistent challenges that prevail in this business, especially in the U.S.
Nevertheless, Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line, going ahead.
Key Picks in the Sector
Some well-ranked medical product stocks that warrant a look NuVasive, Inc. , GW Pharmaceuticals plc and Nxstage Medical, Inc. . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Boston Scientific's Restructuring Plan & Innovation Offer Hope
On Jul 13, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) . The stock currently carries a Zacks Rank #2 (Buy).
We are currently looking forward to the company’s recently introduced global restructuring plan, the execution of which will result in the fulfillment of its margin leverage goals and help produce low-to-mid-teens EPS growth, ahead of the industry average.
Without revealing much detail, the company noted that the program will focus on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of its Plant Network Optimization (PNO) strategy, and expanding operational efficiencies to support its operating income margin goals.
Management has chalked out several key activities under the program, which include strengthening global infrastructure through evolving global real estate and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions, and continued implementation of the company's ongoing PNO strategy. This strategy is intended to simplify Boston Scientific's manufacturing plant structure by transferring certain production lines among facilities. These activities are expected to be initiated in the second quarter of 2016 and substantially completed by year-end 2018.
We are also encouraged about National Institute for Health and Care Excellence’s (NICE) positive guidance on Boston Scientific’s GreenLight XPS Laser Therapy System, for the treatment of prostatic enlargement, known as benign prostatic hyperplasia.
We have noted that the company continues to strengthen its core businesses and invest in new technologies and global markets, which accounted for the sales upside across most of its businesses and regions in the reported quarter. According to Boston Scientific, its PNO strategy has simplified its manufacturing plant structure by shifting certain production lines among facilities. The full benefit of PNO, which has been completed recently, should start to reflect in the company’s Rhythm Management adjusted operating margin through the second half of 2016.
An important aspect of the company’s growth strategy is to continue pursuing development opportunities outside the U.S. by expanding global presence, inclusive of the emerging markets. In the first quarter of 2016, business from the emerging markets registered a robust 21% organic growth rate, well ahead of the company’s target of reaching 15% of sales by 2017 from 8% in 2013.
Boston Scientific hopes to sustain its strong overall international performance taking into concern several key new product launches that are in the early stages of their rollout. The company is also optimistic about its core cardiology segment which is gradually stabilizing, with growth witnessed in the BRIC nations.
Meanwhile, sluggish Cardiac Rhythm Management (CRM) sales over the recent past continue to weigh on the stock. Although Boston Scientific currently expects a rebound in its CRM performance in the second quarter and second-half of 2016, we remain on the sidelines based on the persistent challenges that prevail in this business, especially in the U.S.
Nevertheless, Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line, going ahead.
Key Picks in the Sector
Some well-ranked medical product stocks that warrant a look NuVasive, Inc. , GW Pharmaceuticals plc and Nxstage Medical, Inc. . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>